[Phase I clinical study of 99mTc-MAG3].
A phase I study was performed in three normal volunteers to evaluate the safety and biodistribution of 99mTc-MAG3 which was developed as a renal scintigraphic and renographic dynamic function agent. There was no significant adverse reaction, change in vital signs and clinical laboratory data by the injection of 99mTc-MAG3. Therefore it is assumed that the safety of the agent is high. Clearance of injected 99mTc-MAG3 from blood was rapid and the agent was excreted into urine. Immediately after administration of the agent, renal dynamic scintigraphy was performed and provided better quality of images and renograms. Peak time in the renogram was about 3 min post injection and residual count rate to the peak count at 20 min after injection was 19.3%. Cumulative urinary excretion during the first 30 min and 3 hr expressed in %Dose was 77.1 +/- 3.5% and 94.1 +/- 2.7%, respectively. Radiation dose estimates calculated with MIRD method, in the highest organ, bladder, is 5.78 mGy/200 MBq, which seems to be within permissible range for routine examination in nuclear medicine. It is concluded that 99mTc-MAG3 is a safe and promising radiopharmaceutical in diagnosis of renal dynamic function.
Ishii
K
K
Department of Radiology, Kitasato University School of Medicine, Kanagawa.
Ishibashi
A
A
Torizuka
K
K
D000328:Adult; D006801:Humans; D007668:Kidney / Q000000981:diagnostic imaging; D008297:Male; D009842:Oligopeptides / Q000493:pharmacokinetics; D015609:Organotechnetium Compounds / Q000493:pharmacokinetics; D011829:Radiation Dosage; D011866:Radioisotope Renography; D014018:Tissue Distribution
D009842:Oligopeptides; D015609:Organotechnetium Compounds